AstraZeneca to collaborate with the Health and Social Care Information Centre in health data initiative
Tuesday, 4 December 2012
AstraZeneca today announced it has signed a memorandum of understanding with the Health and Social Care Information Centre (HSCIC) to improve the usefulness of real-world data in healthcare decision making and better understand the role medicines play in helping patients with chronic diseases in England.
This collaboration is the first of its kind between a pharmaceutical company and the HSCIC, England's central, authoritative source of health and social care information, and will support the wider U.K. Government Life Sciences strategy and Growth Agenda. Together AstraZeneca and the HSCIC will develop important capabilities for linking disparate sources of real-world health information from the National Health Service for healthcare decision-making and business intelligence purposes, while adhering to strict information governance principles ensuring patient confidentiality.
The parties will initially look at how anonymised, integrated health data can be used to identify unmet clinical need in patients with diabetes. In the UK, diabetes affects approximately 2.9 million adults overall, with more than 90% of these patients having type 2 diabetes. This makes diabetes one of the most common chronic medical conditions and represents a significant strain on U.K. health services.
Martin Mackay, President of Research and Development for AstraZeneca, said:
AstraZeneca is pleased to work with the HSCIC towards improving the use of health and care data in England, enabling AstraZeneca to assess how medicines impact patient populations and healthcare systems.
AstraZeneca has already established a collaborative agreement with IMS Health, a leading provider of information, services and technology for the healthcare sector, to advance the use of observational and retrospective data studies throughout Europe to inform the delivery of effective and cost-efficient healthcare. AstraZeneca also maintains a ‘real-world’ data and research partnership with HealthCore in the US, the health outcomes research subsidiary of WellPoint.
NOTES TO EDITORS
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
+1 610 999 8330